Coyne Karin S, Barsdorf Alexandra I, Mazière Jean-Yves, Pierson Renee F, Lanza Stephanie T, Farrar John T, Gelfand Capt Harold J, Porter Leslie N, Schnoll Sidney H, Butler Stephen F
Evidera, Bethesda, MD, USA.
Clinical Outcomes Solutions LLC, Chicago, IL, USA.
Curr Med Res Opin. 2023 Mar;39(3):441-450. doi: 10.1080/03007995.2023.2174343. Epub 2023 Feb 10.
To identify patient risk factors associated with prescription opioid misuse and abuse as well as groupings of misuse and abuse behaviors as measured by the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ).
Adults with chronic pain requiring long-term treatment with opioids completed the POMAQ and other study questionnaires. Latent class analysis (LCA) was used to examine underlying subgroups exhibiting particular risk profiles. Patient demographic and clinical characteristics were examined as covariates and the concordance between the identified latent classes at-risk classifications and the POMAQ clinical scoring algorithm was assessed.
Analysis of data from 809 patients revealed four classes: "chronic pain, low risk" ( = 473, low to no prevalence of POMAQ behaviors), "chronic pain, comorbid condition" ( = 152, high prevalence of anti-anxiety, sleeping pill, and antihistamine use), "at risk" ( = 154, taking more opioids than prescribed and drinking alcohol with opioids more frequently than other groups), and "high risk" ( = 30, highest prevalence of each behavior). The "high risk" group was associated with being younger, less educated, and unemployed compared to other groups. When examining the LCA classes by groups defined by the original POMAQ clinical scoring algorithm, the "high risk" class had the highest proportion of participants identified with abuse behaviors (46.7%), compared to just 4.7% in the "chronic pain, low risk" group.
Findings suggest there are four distinct subgroups of patients defined by chronic opioid misuse and abuse behaviors and support the use of the POMAQ to identify risk factors associated with prescription opioid misuse and abuse.
通过处方阿片类药物滥用问卷(POMAQ)来确定与处方阿片类药物滥用及误用相关的患者风险因素,以及滥用和误用行为的分组情况。
需要长期使用阿片类药物治疗慢性疼痛的成年人完成了POMAQ及其他研究问卷。采用潜在类别分析(LCA)来检查呈现特定风险特征的潜在亚组。将患者的人口统计学和临床特征作为协变量进行检查,并评估所确定的潜在风险类别与POMAQ临床评分算法之间的一致性。
对809名患者的数据进行分析后发现了四个类别:“慢性疼痛,低风险”(n = 473,POMAQ行为的患病率低或无),“慢性疼痛,合并症”(n = 152,抗焦虑药、安眠药和抗组胺药的使用率高),“有风险”(n = 154,服用的阿片类药物超过处方量,且与其他组相比,更频繁地在服用阿片类药物时饮酒),以及“高风险”(n = 30,每种行为的患病率最高)。与其他组相比,“高风险”组的患者更年轻、受教育程度更低且失业。当按照原始POMAQ临床评分算法定义的组来检查LCA类别时,“高风险”类别中被确定有滥用行为的参与者比例最高(46.7%),而“慢性疼痛,低风险”组中这一比例仅为4.7%。
研究结果表明,慢性阿片类药物滥用和误用行为可将患者分为四个不同的亚组,并支持使用POMAQ来识别与处方阿片类药物滥用和误用相关的风险因素。